2445 Results for "

ATP

" in MedChemExpress (MCE) Product Catalog:
Products (2445)

2445 Results for "ATP" in MCE Product Catalog:

87
87 Cited Publications
Cat. No.: HY-15777
CAS No.: 1211441-98-3
Purity:  99.94%
Synonyms: LEE011
Target:  

CDK

Research Areas:  

Neurological Disease Cancer

RRibociclib (LEE011) is an ATP-competitive and orally active CDK4/6 inhibitor that crosses the blood-brain barrier with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex .
loading...
    loading...
87
87 Cited Publications
Cat. No.: HY-15777A
CAS No.: 1211443-80-9
Purity:  99.93%
Synonyms: LEE011 hydrochloride
Target:  

CDK

Research Areas:  

Neurological Disease Cancer

RRibociclib (LEE011) hydrochloride is an ATP-competitive and orally active CDK4/6 inhibitor that crosses the blood-brain barrier with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex .
loading...
    loading...
87
87 Cited Publications
Cat. No.: HY-15777B
CAS No.: 1374639-75-4
Purity:  99.93%
Synonyms: LEE011 succinate
Target:  

CDK

Research Areas:  

Neurological Disease Cancer

RRibociclib (LEE011) succinate is an ATP-competitive and orally active CDK4/6 inhibitor that crosses the blood-brain barrier with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex .
loading...
    loading...
87
87 Cited Publications
Cat. No.: HY-15777C
CAS No.: 1374639-79-8
Purity:  99.94%
Synonyms: LEE011 succinate hydrate
Target:  

CDK

Research Areas:  

Cancer

RRibociclib (LEE011) succinate hydrate is an ATP-competitive and orally active CDK4/6 inhibitor that crosses the blood-brain barrier with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex .
loading...
    loading...
85
85 Cited Publications
Cat. No.: HY-14660
CAS No.: 1195765-45-7
Purity:  99.94%
Synonyms: GSK2118436A; GSK2118436
Target:  

Raf CDK

Research Areas:  

Cancer

Dabrafenib (GSK2118436A) is an ATP-competitive inhibitor of Raf with IC50s of 5 nM and 0.6 nM for C-Raf and B-Raf V600E, respectively .
loading...
    loading...
73
73 Cited Publications
Cat. No.: HY-10422
CAS No.: 1009298-09-2
Purity:  99.60%
Target:  

mTOR Autophagy Apoptosis

Research Areas:  

Cancer

AZD-8055 is a potent, selective, and orally bioavailable ATP-competitive mTOR kinase inhibitor with an IC50 of 0.8 nM. AZD-8055 inhibits both mTORC1 and mTORC2 .
loading...
    loading...
69
69 Cited Publications
Cat. No.: HY-15186A
CAS No.: 1396257-94-5
Purity:  99.09%
Synonyms: GDC-0068 dihydrochloride; RG-7440 dihydrochloride
Target:  

Organoid Akt

Research Areas:  

Cancer

Ipatasertib dihydrochloride (GDC-0068 dihydrochloride) is a highly selective and ATP-competitive pan-Akt inhibitor with IC50s of 5, 18 and 8 nM for Akt1, Akt2 and Akt3, respectively.
loading...
    loading...
69
69 Cited Publications
Cat. No.: HY-15186
CAS No.: 1001264-89-6
Purity:  99.79%
Synonyms: GDC-0068; RG7440
Target:  

Organoid Akt Apoptosis

Research Areas:  

Cancer

Ipatasertib (GDC-0068) is an orally active, highly selective and ATP-competitive pan-Akt inhibitor with IC50 values of 5, 18, 8 nM for Akt1/2/3, respectively. Ipatasertib synchronously activates FoxO3a and NF-κB through inhibition of Akt leading to p53-independent activation of PUMA. Ipatasertib also induces apoptosis in cancer cells and inhibits tumor growth in xenograft mouse models .
loading...
    loading...
67
67 Cited Publications
Cat. No.: HY-13805
CAS No.: 172889-27-9
Purity:  98.34%
Synonyms: AGL 1879
Target:  

Src

Research Areas:  

Cancer

PP2 is a reversible and ATP-competitive Src family kinases inhibitor with IC50s of 4 and 5 nM for Lck and Fyn, respectively.
loading...
    loading...
67
67 Cited Publications
Cat. No.: HY-13820
CAS No.: 1337532-29-2
Purity:  99.66%
Target:  

PERK Autophagy Apoptosis

Research Areas:  

Cancer

GSK2656157 is a selective and ATP-competitive inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) with an IC50 of 0.9 nM.
loading...
    loading...
67
67 Cited Publications
Cat. No.: HY-50876
CAS No.: 658084-64-1
Synonyms: FK866; APO866
Research Areas:  

Cancer

Daporinad (FK866) is a non-competitive inhibitor of nicotinamide phosphoribosyltransferase (Nampt), with a Ki value of 0.3 nM. Daporinad depletes NAD+ and ATP levels, inhibits mTORC1 and MAPK/ERK pathways, and activates TFEB to induce autophagy. Daporinad causes the depletion of the endoplasmic reticulum Ca²⁺ pool, ultimately weakening the mitogen-induced Ca²⁺ signal and the activation and function of T cells. Daporinad induces cell cycle arrest and apoptosis, and inhibits cell proliferation. Daporinad can be used for the study of myeloma, liver cancer, and immunosuppression .
loading...
    loading...
65
65 Cited Publications
Cat. No.: HY-112654
CAS No.: 2183470-12-2
Purity:  99.83%
GCN2iB is an ATP-competitive, selective GCN2 inhibitor with an IC50 of 2.4 nM. GCN2iB inhibits the activation of the GCN2 pathway and upregulates GPX4. GCN2iB enhances the anticancer effect of ASNase against acute lymphoblastic leukemia. GCN2iB increases left ventricular ejection fraction, while reducing fasting blood glucose and myocardial fibrosis. GCN2iB can be used in research related to acute lymphoblastic leukemia, acute myeloid leukemia and diabetic cardiomyopathy .
loading...
    loading...
57
57 Cited Publications
Cat. No.: HY-14881A
CAS No.: 845533-86-0
Purity:  99.97%
Synonyms: R403323; TMC207 fumarate; R207910 fumarate
Target:  

Bacterial Antibiotic

Research Areas:  

Infection

Bedaquiline fumarate, a diarylquinoline antibiotic that targets ATP synthase, is effective for the treatment of Mycobacterium tuberculosis infections.
loading...
    loading...
57
57 Cited Publications
Cat. No.: HY-14731
CAS No.: 1232410-49-9
Purity:  99.67%
Target:  

ATM/ATR

Research Areas:  

Cancer

VE-821 is a potent ATP-competitive inhibitor of ATR with Ki/IC50 of 13 nM/26 nM.
loading...
    loading...
57
57 Cited Publications
Cat. No.: HY-14881
CAS No.: 843663-66-1
Purity:  99.98%
Synonyms: TMC207; R207910
Target:  

Bacterial Antibiotic

Research Areas:  

Infection

Bedaquiline (TMC207) is a diarylquinoline agent and inhibits Mycobacterium tuberculosis (Mtb) F1FO-ATP synthase through targeting of both the c- and the ε-subunit . Bedaquiline has uncoupler activity. Bedaquiline is used for the multi-agent resistant tuberculosis .
loading...
    loading...
57
57 Cited Publications
Cat. No.: HY-13328
CAS No.: 1224844-38-5
Purity:  99.63%
Synonyms: INK-128; MLN0128; TAK-228
Sapanisertib (INK-128; MLN0128; TAK-228) is an orally active dual mTORC1/mTORC2 inhibitor. Sapanisertib directly and simultaneously inhibits mTORC1/2 activity through competitive binding with ATP, thereby comprehensively blocking downstream processes such as protein and lipid synthesis and cytoskeletal reorganization, consequently suppressing tumor cell proliferation and promoting apoptosis. Sapanisertib is applicable to research on melanoma, ovarian cancer, pulmonary fibrosis, and hematological malignancies .
loading...
    loading...
56
56 Cited Publications
Cat. No.: HY-16589
CAS No.: 579-13-5
Synonyms: MCH 32
Oligomycin A (MCH 32), created by Streptomyces, acts as a mitochondrial F0F1-ATP synthase inhibitor, with a Ki of 1 μM; Oligomycin A shows anti-fungal activity.
loading...
    loading...
55
55 Cited Publications
Cat. No.: HY-10006
CAS No.: 131740-09-5
Purity:  99.73%
Synonyms: Alvocidib Hydrochloride; L86-8275 Hydrochloride; HMR-1275 Hydrochloride
Target:  

CDK Autophagy HIV

Research Areas:  

Cancer

Flavopiridol Hydrochloride (Alvocidib Hydrochloride) is a broad inhibitor of CDK, competing with ATP to inhibit CDKs including CDK1, CDK2, CDK4 with IC50s of 30, 170, 100 nM, respectively.
loading...
    loading...
55
55 Cited Publications
Cat. No.: HY-10409
CAS No.: 936091-26-8
Purity:  99.83%
Synonyms: TG-101348; SAR 302503
Target:  

JAK Apoptosis

Research Areas:  

Cancer

Fedratinib (TG-101348) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib induces cancer cell apoptosis and has the potential for myeloproliferative disorders research .
loading...
    loading...
55
55 Cited Publications
Cat. No.: HY-10409A
CAS No.: 1374744-69-0
Purity:  99.92%
Synonyms: TG-101348 hydrochloride hydrate; SAR 302503 hydrochloride hydrate
Target:  

JAK Apoptosis

Research Areas:  

Cancer

Fedratinib hydrochloride hydrate (TG-101348 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib hydrochloride hydrate shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib hydrochloride hydrate induces cancer cell apoptosis and has the potential for myeloproliferative disorders research .
loading...
    loading...